An estimated 15 million U.S. adults currently use GLP-1 receptor agonist medications such as semaglutide and tirzepatide, with that figure projected to reach 30 million by 2030. The global GLP-1 drugs market size began at US$ 52.95 billion in 2025 and is forecast to rise to US$ 58.05 billion by 2026. By the end of 2035, it is expected to surpass US$ 132.79 billion, growing steadily at a CAGR of 9.63%.
Behind this growth is a patient group with needs that the drug alone does not address: reduced appetite, digestive discomfort, muscle loss risk, and lower fiber intake. This is creating a new product design challenge for F&B R&D teams.
Since 2023, more than a dozen branded products targeting GLP-1 users have entered the U.S. market. Nestlé, Abbott, PepsiCo, and General Mills have moved from observation to product execution. ADM has built a 25-concept product platform around this population. Tate & Lyle invested €25 million to expand fiber production capacity and spent $1.8 billion acquiring CP Kelco to strengthen its ingredient portfolio.
The commercial market is moving fast, but the patent space around fiber-GLP-1 nutrition remains open. For R&D teams, the opportunity is clear. Fiber-fortified GLP-1 products need to solve three problems at once: commercial fit, digestive tolerance, and defensible IP.
Using Slate – R&D intelligence platform, we analyzed the GLP-1 fiber-fortified products across research papers, product launches, supplier moves, clinical evidence, and patent filings. The goal was to separate credible science from market noise and identify where F&B R&D teams can still build differentiated products.
Why GLP-1 Users Need Better Nutrition Design
GLP-1 users often eat less. Many also deal with nausea, constipation, delayed gastric emptying, altered taste, and muscle loss risk. A standard low-calorie product does not address these needs.
A better product has to work in a smaller portion. It needs to support protein intake, fiber intake, hydration, and digestive comfort without adding gut burden.
Fiber sits at the center of this need. Fermentable fibers can support short-chain fatty acid production in the gut. These short-chain fatty acids can stimulate L-cells, which release GLP-1 and PYY, two hormones linked to fullness and appetite control.
For R&D teams, the key point is simple: fiber type matters as much as fiber amount. The same fiber gram count can lead to different outcomes depending on viscosity, fermentation speed, dose, and food matrix.
What the First Wave of GLP-1 Nutrition Products Reveals?
The commercial landscape now splits into two camps.
Digital-native brands lead with fiber transparency, clinical citations, and more direct GLP-1 language. Legacy CPG players move through scale, lower price points, and safer nutrient-content claims.
| Brand | Company | Format | Fiber dose and type | Commercial signal | R&D readout |
| Pro-Fiber | Lactalis USA | Dairy snack cup | 10g proprietary blend | First GLP-1-friendly functional dairy, $1.66 per cup, Target distribution | Dairy is becoming a credible GLP-1 format, but fiber blend details remain limited |
| Vital Pursuit | Nestlé | Frozen bowls, melts, pizzas | Variable, whole grains, and protein pasta | 12 SKUs priced at $4.99 or less, portion-aligned, air-fryer ready | Strong mass-market execution, but conservative claims and limited fiber specificity |
| Healthy Choice “On Track” | Conagra | Café Steamers and Simply Steamers | “Good fiber,” type unspecified | 26 items, $3.49 to $3.99, high protein and low calorie | Shows fast category entry, but weak technical transparency |
| PROTALITY | Abbott | RTD shake | 4g fiber, type unspecified | 30g protein, 150 kcal, 1g sugar, $13.69 per 4-pack | Protein-led GLP-1 nutrition, but fiber is secondary |
| GLP-1 Support Box | Daily Harvest | Frozen smoothies | 6g to 11g plant-based fiber | $109 box, HSA/FSA eligible, Noom partnership | Digital-native model links nutrition, access, and behavior support |
| GLP-1 Daily Support | Supergut | Powder | 6g, Solnul RS, Sunfiber guar, oat beta-glucan, green banana resistant starch | $29.99, Target, GNC, “natural Ozempic” positioning | Strongest fiber transparency among listed products |
| GLP-1 Probiotic | Pendulum | Capsule and prebiotic powder | 211mg chicory inulin in capsule, 6g fiber in Gut Fuel powder | 91% craving reduction in 274-person, 6-week consumer study | Points to fiber-probiotic convergence as the next competitive front |
The gap between these two camps is important. Digital-native brands disclose fiber types, doses, and clinical rationale. Legacy brands often use “good source of fiber” language without naming the fiber or dose.
That gives R&D teams a clear route to differentiation. A product that names the fiber type, supports the dose with evidence, and explains tolerance can stand apart from generic high-fiber positioning.
The 10g fiber dose from Fibersol-2 and PROMITOR studies is one of the clearest reference points in the market. Yet many large-brand products do not specify fiber type or dose. That is a formulation credibility gap waiting to be closed.
Which Fiber Suppliers Have the Data to Support Health Claims?
No exclusive supply agreements between brands and ingredient suppliers have been disclosed. Supergut sources Solnul, Sunfiber, and oat beta-glucan through standard commercial procurement. Tate & Lyle’s CP Kelco acquisition was a horizontal portfolio move, not a GLP-1-specific lock-in.
This means supplier advantage comes from clinical support, formulation fit, and claim relevance rather than exclusivity.
| Supplier | Key Ingredient | Evidence from the Report | R&D Implication |
| ADM | Fibersol-2, resistant tapioca starch | 10g dose significantly raised GLP-1 and PYY, with 1.5 to 2-hour hunger delay. Tolerated up to 68g per day. ADM research found 83% of GLP-1 medication users find GLP-1-targeted foods appealing, and 49% have increased fiber intake | Strong option for satiety-led products with claim support |
| Tate & Lyle | PROMITOR soluble corn fiber | Tolerated at 40g to 65g per day. A 10g dose delayed hunger by 1.5 to 2 hours. Backed by a 500-person GLP-1 user behavioral study | Strong fit for low-viscosity formats and scalable food applications |
| BENEO | Palatinose, Orafti inulin and oligofructose | 50g Palatinose produced about 6.3 times higher and longer GLP-1 release versus sucrose. In type 2 diabetes patients, peak GLP-1 was twice as high and stayed elevated for 6 hours | Useful for metabolic positioning, but dose and format fit need review |
| Roquette | NUTRIOSE resistant dextrin | 34g per day produced 2.3 kg weight loss versus placebo and reduced metabolic syndrome prevalence from 27% to 12% | Relevant for weight management and metabolic health formats |
| Ingredion | HI-MAIZE 260 | 40g per day over 8 weeks produced 2.8 kg weight loss and enriched beneficial gut bacteria | Strong microbiome angle, but dose may limit use in small-serving products |
Three emerging suppliers are worth tracking before their clinical validation increases their commercial value.
Akarso Bio has a fermented fiber platform targeting GLP-1 stimulation through short-chain fatty acid production. It claims neutral taste and flexible texture, with pilot-scale supply and provisional patents.
CarobWay is developing CarobBiome, an ingredient with about 85% fiber, reduced bloating potential, and antioxidant properties. It is expected to be showcased at IFT FIRST in July 2025.
The Lupin Co offers LupinQ, a commercial ingredient with 50% fiber and 40% protein. It is positioned as a food-based GLP-1 activator and is relevant for pasta, bakery, and meal replacement formats.
How Is the GLP-1 Fiber Patent Landscape Taking Shape?
| Assignee | Patent or family | Focus | GLP-1 relevance | Strategic implication |
| Food Sciences Corp. | US2025177457A1 | Supplement for people taking a GLP-1 agonist, with whey, leucine, flaxseed, enzymes, probiotics, and prebiotic fibers | Direct GLP-1 adjunct positioning | Most important explicit filing. R&D teams should map around it before filing similar claims |
| Undisclosed | KR102916795B1 | Alpha-cyclodextrin, L-glutamine, moringa, lactoferrin, FOS, XOS, inulin | Positions itself as a natural GLP-1 secretion aid | Competes with pharma-style GLP-1 positioning, higher claim risk |
| Leeuwenhoek Laboratories | US2026000719A1 | Lychee polyphenols plus B. animalis, B. longum, and methionine | Synbiotic composition for GLP-1 increase and Akkermansia elevation | Signals rising patent activity around microbiome-linked GLP-1 support |
| Meiji Co. | TWI791738B | Fermented milk, dietary fiber, and oligosaccharides | Diabetes and impaired glucose tolerance | Useful precedent for dairy, fiber, and prebiotic combinations |
| Nestlé | WO2022268759A1 and equivalents | Fiber plus probiotic combinations for microbiome resilience | No explicit GLP-1 claim | Key FTO watchpoint for synbiotic GLP-1 products |
| General Mills | WO2025160518A1, US2025241337A1, WO2022109283A1 | High-protein and high-fiber extruded pieces, texture-controlled viscous fiber | No explicit GLP-1 claim | Processing IP may matter for snacks, cereals, and compact food formats |
| Abbott | WO2023205762A1 | BPL1 probiotic plus resistant starch for slowing diabetes development | No GLP-1 secretion claim | Relevant to metabolic nutrition but not direct GLP-1 fiber positioning |
| Kellogg | US11324241B2 | Prebiotic snack bars with inulin binders and yogurt probiotic coatings | No GLP-1 claim | Useful snack-format precedent, but not a direct GLP-1 barrier |
Most patent activity in this space comes from Chinese entities, including Yili, Qingdao Marine Biological Medicine, and Beijing Guarerrun, along with a small group of specialty developers. Major Western fiber suppliers such as ADM, Tate & Lyle, and BENEO rely more on trade secrets, clinical data, and formulation expertise than on composition-of-matter patents.
Which Patent White Spaces Are Still Open in GLP-1 Fiber Products?
Patent white space remains open across six areas where R&D and IP teams can still build defensible positions.
| White Space | Current Activity | Why it Matters | What R&D Can Build |
| GLP-1 adjunct nutrition | One direct filing from Food Sciences Corp. | Large gap between drug use and nutrition support | Protein-fiber formats for users on GLP-1 therapy |
| GI side effect support | Limited patent activity | Nausea, bloating, constipation, and early fullness drive product failure | Low-viscosity fiber systems, PHGG, RS4, and slow-fermentation blends |
| SCFA-targeted blends | Some academic and mechanism-led filings | Butyrate and propionate pathways connect fiber to gut hormone response | Fiber ratios designed around SCFA output rather than total fiber grams |
| Fiber-protein compact meals | General Mills has processing patents | GLP-1 users need nutrient density in smaller portions | Bars, shakes, soups, cups, and meal replacements with protein and tolerable fiber |
| Dose-escalation systems | Minimal activity | Users may need 5g to 10g starting doses with 2 to 4 week titration | Starter, step-up, and maintenance product systems |
| Fiber-probiotic synbiotics | Nestlé has broad microbiome resilience IP | This is becoming more crowded | FTO review before combining fiber with Akkermansia, Bifidobacterium, or other live strains |
The strongest near-term filing areas are GI tolerance, dose escalation, and SCFA-targeted fiber ratios. These areas solve real product problems and avoid some of the claim risk linked to direct GLP-1 hormone language.
Where Are the Real Competitive Gaps?
The commercial shelves are filling, but the strategic gaps remain clear.
The first gap is fiber transparency. Many legacy products still use “good source of fiber” language without dose, type, or supporting evidence. Brands that disclose fiber type and dose can build more credibility with R&D buyers, dietitians, and informed consumers.
The second gap is clinical validation in GLP-1 users. No randomized controlled trial has tested fiber supplementation in people actively taking GLP-1 medicines. Most current product logic comes from adjacent groups such as people with IBS, bariatric surgery patients, or type 2 diabetes cohorts. A dedicated tolerability study in GLP-1 users would support claims, product design, and IP filings.
The third gap is early supplier access. Akarso Bio, CarobWay, and The Lupin Co are still at or before broad peer-reviewed validation. Companies that evaluate these platforms early may secure better terms or stronger collaboration rights before the market consolidates around proven endpoints.
The fourth gap is the freedom to operate in fiber-probiotic products. Nestlé’s WO2022268759A1 family and related filings should be reviewed before locking any formulation that combines fiber with live bacterial strains for GLP-1-adjacent benefits.
How SLATE Helps R&D Teams Track This Market
Fiber-fortified products for GLP-1 users have moved beyond trend-based positioning. The category now needs disciplined product design, where commercial moves, supplier claims, clinical evidence, patent filings, and regulatory risks are tracked together.
This is where Slate helps R&D and innovation teams. Slate monitors product launches, supplier investments, claim changes, clinical evidence, and patent activity across relevant F&B categories. When a GLP-1-targeted SKU launches, a supplier secures new evidence, or a patent appears in a target white space, teams can assess what it means for formulation, claims, and IP strategy.
For R&D teams, this matters because delayed intelligence can lead to late supplier decisions, crowded claims, or avoidable FTO risks. The strongest brands in GLP-1 nutrition will not be the ones with the highest fiber count. They will be the ones that solve the full user need: reduced appetite, gut tolerance, muscle support, bowel regularity, taste shifts, and safe claim language.
Slate gives teams the visibility to track those shifts early, so they can build evidence-backed products before the market converges around a few proven formats.
